ArticleIDCases2025
Autoimmune encephalitis associated with anti-SOX1 autoantibodies in COVID-19: A case report.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Higher expression of SOX1, miR-155, and miR-21 in the colostrum of SARS-CoV-2-infected mothers.Scientific reports · 2026Article
- Case Report: A case of paraneoplastic autoimmune encephalitis with concurrent anti-GABABR and anti-SOX1 antibody positivity.Frontiers in cellular neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) might be complicated by various non-respiratory conditions, including encephalitis. Encephalitis in COVID-19 represents a heterogenous group of diseases with variable aetiology. Autoimmune encephalitis (AIE) is the least common but one of the most severe causes of encephalopathy in COVID-19. AIE is a rare disease that is associated with different types of autoantibodies mostly directed against various neuronal antigens. Anti-Sry-like high mobility group box (SOX1) autoantibodies have been described in various clinical conditions, including Lambert-Eaton myasthenic syndrome, paraneoplastic cerebellar degeneration and rare cases of paraneoplastic AIE. We present the case of 28-year-old female patient with COVID-19 confirmed by the polymerase chain reaction (PCR) test. She was admitted with fever, headache, disorientation and new-onset refractory status epilepticus. Computed tomography and magnetic resonance imaging of the brain were unremarkable. Cerebrospinal fluid analysis showed pleocytosis, an increased total protein concentration and increased albumin and immunoglobulin G. Electroencephalography revealed findings suggestive of AIE. Serologic examination of antineuronal antibodies showed anti-SOX1 autoantibodies. A course of parenteral methylprednisolone and intravenous immunoglobulin led to rapid clinical improvement. The patient was discharged free of seizures as well as neurologic and psychiatric symptoms. After discharge, an oncologic screening was performed and ruled out a paraneoplastic aetiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.